FDA Eases Risk Mandates For GSK, Amgen Platelet Drugs
The U.S. Food and Drug Administration has eased risk mitigation requirements for GlaxoSmithKline PLC's Promacta and Amgen Inc.'s Nplate, which treat low platelet counts, the FDA said Tuesday, adding that both...To view the full article, register now.
Already a subscriber? Click here to view full article